ABACUS MEDICINE A/S: Financial statements 2023
CVR: 28111576
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
ABACUS MEDICINE A/S (CVR 28111576) has filed annual accounts for 2023. In 2023, the company reported revenue of EUR 1,210,354,000 and a net result of EUR 20,042,000 compared with EUR 5,819,000 the year before. That is an increase of 18.2% compared with the year before. The profit margin was 1.7%. Equity in the 2023 report amounted to EUR 80,866,000. The solvency ratio was 25.4%.
- Revenue
- EUR 1,210,354,000
- Profit/Loss
- EUR 20,042,000
- Equity
- EUR 80,866,000
- Total Assets
- EUR 318,940,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | 1.2B EUR | - | 20M EUR | 80.9M EUR | - |
| 2022 | 1B EUR | - | 5.8M EUR | 61M EUR | - |
| 2021 | 940.7M EUR | - | 415K EUR | 54.6M EUR | - |
| 2020 | 663.5M EUR | - | 433K EUR | 53M EUR | - |
| 2019 | 421.4M EUR | - | 829K EUR | 51.6M EUR | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
ABACUS MEDICINE A/S has published its annual report for 2022. Revenue came to DKK 1,023,978,000, and the net result was DKK 5,819,000.
About ABACUS MEDICINE A/S
ABACUS MEDICINE A/S is a Danish company of the type Aktieselskab based in København V, founded in 2004. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named ABACUS MEDICINE ApS. The management consists of Flemming Wagner. The board consists of Jens Albert Harsaae (chair), Alette Margaretha Verbeek, Anders Kunze Bønding and Flemming Wagner. The company is owned by Wagner Family Holding ApS and CHR. AUGUSTINUS FABRIKKER AKTIESELSKAB. The company has 388 employees (2026). In 2025, the company reported revenue of EUR 1,817,637,000 and a net result of EUR 7,779,000 compared with EUR 17,621,000 the year before. Equity in the 2025 report amounted to EUR 98,523,000.